Ulcerative Colitis
Conditions
Brief summary
Combination Therapy with Drug and Diet for Induction of Remission in Mild to Moderate Active Pediatric Ulcerative colitis: A Single Blinded, International Randomized Controlled Trial
Detailed description
This will be a 12 week, single blinded Randomized controlled trial (RCT) in children and adolescents with mild to moderate Ulcerative Collitis (UC) comparing 5ASA (recommended dosing 60-75 mg/kg/day; minimum 2.5 maximum 4 grams/day) with fiber restriction for 6 weeks followed by free diet (Group 1) to 5ASA with Ulcerative Collitis Diet (UCD) for 6 weeks, followed by the step down UCD for the next 6 weeks. Inclusion criteria will include children weighing \>30kg, Pediatric Ulcerative Collitis Activity index (PUCAI) 10-45, no treatment with 5ASA (treatment naïve or treated with thiopurines for example) or currently treatment with 5ASA but \<2 grams/day, ages 10-19 years, with disease extent E2-E4 by the Paris Classification. Patients on thiopurines may continue existing dose if dose is stable for at least 8 weeks. Exclusion criteria are Patients with acute severe colitis (ASC) in the previous year, requiring oral or intravenous steroids in the previous 3 months, or patients treated with Anti- Tumor necrosis factor alfa (TNFa) regimens. Importantly, there is no placebo arm and both groups will be treated with the same currently recommended drug at currently recommended doses; the only difference between groups being their diets. The primary endpoint will be remission defined as PUCAI\<10 at week 6; Secondary endpoints will be response defined as a drop in PUCAI of 10 or remission at week 6, sustained steroid free remission week 12 and improvement in mucosal healing by Ulcerative Colitis Endoscopic Index of Severity (UCEIS) at week 12 as well as safety and tolerance. Intolerance will be defined as patients stopping the diet because of refusal to continue diet. Patients will be seen at weeks 0, 3, 6, and 12. PUCAI will be assessed at every visit; fecal calprotectin will be assessed at baseline, week 6 and 12. Sigmoidoscopy to assess mucosal healing will be performed at week 12 in patients who had a baseline colonoscopy or sigmoidoscopy. Sigmoidoscopies to evaluate healing will be voluntary and patients will not be excluded if they do not consent to have a follow up sigmoidoscopy.
Interventions
DIETARY_SUPPLEMENTGroup 1- Control Diet
Oral 5ASA+ Low Residue Diet for 6 weeks and Oral 5ASA+ Free Diet for 6 more weeks
DIETARY_SUPPLEMENTGroup 2- UCD Diet
Oral 5ASA+ UC Diet for 6 weeks and Oral 5ASA+ UC Diet Stage 2 for 6 more weeks
Sponsors
Prof. Arie Levine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Masking description
Physicians will be blinded to the randomization and dietary advice received
Eligibility
Sex/Gender
ALL
Age
10 Years to 19 Years
Healthy volunteers
No
Inclusion criteria
1. Informed consent 2. Established diagnosis of UC by the Paris classification and Revised Porto Criteria. 3. Age: 10 - 19 years (inclusive) 4. Mild to moderate active disease, 10 ≤ PUCAI ≤45 5. Extent E2-E4 by the Paris classification 6. Weight \>30 kg (ensures that patients who received 5ASA ≤2 grams are eligible) 7. Stable medication (IMM/ 5ASA) use or no change in medication use for the past 6 weeks. Patients who have received topical 5ASA therapy for \<10 days and are active may be included if topical therapy is stopped at enrolment. 8. Patients not receiving 5ASA or using 5ASA\<50mg/kg/day
Exclusion criteria
1. Any proven current infection such as positive stool culture, parasite or C. difficile. 2. Steroids (oral or intravenous) use in the past 3 months. 3. Patients who continue topical 5ASA or steroids after enrolment 4. Use of biologics in present or in past 6 months 5. Use of antibiotics for more than one week in the past 60 days 6. PUCAI \>45 7. Acute severe UC in the previous 12 months. 8. Current extra intestinal manifestation of UC. 9. Primary Sclerosing Cholangitis (PSC) or Liver disease 10. Pregnancy. 11. Vegans or patients unwilling or unable to consume eggs 12. Inflammatory Bowel Disease (IBD) unclassified
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PUCAI< 10 at week 6 | 6 weeks | Remission defined as PUCAI\<10 at week 6 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean/median change in Calprotectin at week 6 | 6 weeks | Mean/median change in Calprotectin at week 6 |
| Sustained remission week 12 | 12 weeks | Sustained steroid & biologic free remission week 12 |
| A drop of PUCAI at least 10 points or remission | 6 weeks | Response defined as a drop of PUCAI at least 10 points or remission (intention to treat) week 6 . |
| Change in UCEIS at week 12 ( optional) | 12 weeks | Change in UCEIS at week 12 ( optional) |
| Tolerance to diet | 12 weeks | Tolerance to diet defined by withdrawal from the study because of difficulties with the diet. |
| Need for topical therapy by week 12 | 12 weeks | Need for topical therapy by week 12 |
Countries
Israel
Outcome results
None listed